Literature DB >> 29773761

Surgical treatment of pancreatic cancer.

Wioletta Masiak-Segit1, Karol Rawicz-Pruszyński2, Magdalena Skórzewska2, Wojciech P Polkowski2.   

Abstract

The only way to cure the patient with adenocarcinoma of the pancreas (RT) is surgical excision of the tumor. The standard surgical treatment of resectable pancreatic carcinoma is considered the classic pancreatoduodenectomy (PD) with the Kausch- Whipple procedure, or the pylorus-preserving PD with the Traverso-Longmire method. The most difficult technically and at the same time the most important PD stage from an oncological point of view is the separation of the head of the pancreas from the superior mesenteric artery. Over the last decades several PD modifications have been developed, focusing on this maneuver in the early phase of the operation, i.e. before the pancreas is cut (an irreversible stage of the procedure). These procedures in the English literature are called "artery-first approach" or "SMA-first approach". The term "mesopancreas" was created. Complete removal of the mesopancreas together with the proximal part of the jejunum is considered an R0 resection in the case of a tumor of the head of the pancreas with direct or indirect vascular invasion, or metastases to regional lymph nodes, and in English literature it is referred to as pancreatoduodenectomy with systematic mesopancreas dissection (SMDPD). Distal resection of the pancreas (DRT) due to cancer, is associated with a high percentage of positive margins, insufficient number of removed lymph nodes, low survival rates. A new technique was developed - a radical proximal-distal modular pancreatosplenectomy (RAMPS). In RAMPS, surgical operations proceed from the side of the pancreas head towards the tail, the pancreas is cut early, and the splenectomy is performed at the final stages of the procedure. Currently, following the PD model, attempts are made to further modify the original RAMPS technique, especially in the direction of SMA-first approach. In patients with borderline resectable pancreatic tumors or locally advanced tumors, after neoadjuvant treatment, a technique of radical resection with preservance of arterial vessels - "the TRIANGLE operation" has been elaborated. Despite the tremendous progress of surgical techniques, RT is still detected too late in the phase preventing effective resection.

Entities:  

Keywords:  distal pancreatic resection; pancreatic cancer; pancreatoduodenectomy

Mesh:

Year:  2018        PMID: 29773761     DOI: 10.5604/01.3001.0011.7493

Source DB:  PubMed          Journal:  Pol Przegl Chir        ISSN: 0032-373X


  9 in total

1.  Magnetic resonance imaging for preoperative staging of pancreatic cancer based on the 8th edition of AJCC guidelines.

Authors:  Yan Deng; Bing Ming; Jia-Long Wu; Ting Zhou; Shi-Yong Zhang; Yong Chen; Chuan Lan; Xiao-Ming Zhang
Journal:  J Gastrointest Oncol       Date:  2020-04

2.  Modular approach in OPHL: are there preoperative predictors?

Authors:  Andy Bertolin; Marco Lionello; Marco Ghizzo; Emanuela Barbero; Erika Crosetti; Giuseppe Rizzotto; Giovanni Succo
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-10       Impact factor: 2.124

Review 3.  Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.

Authors:  Dannel Yeo; Althea Bastian; Heidi Strauss; Payal Saxena; Peter Grimison; John E J Rasko
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

4.  FGD5‑AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/β‑catenin signaling pathway via miR‑577.

Authors:  Wei-Tao Zhang; Ji-Jun Zhang; Quan Shao; Ying-Kai Wang; Jie-Peng Jia; Bo Qian; Xiao-Wen Tian; Wen-Ji Yan
Journal:  Oncol Rep       Date:  2021-11-25       Impact factor: 3.906

Review 5.  The next wave of cellular immunotherapies in pancreatic cancer.

Authors:  Dannel Yeo; Caroline Giardina; Payal Saxena; John E J Rasko
Journal:  Mol Ther Oncolytics       Date:  2022-02-01       Impact factor: 7.200

6.  Impact of Fatty Pancreas on Postoperative Pancreatic Fistulae: A Meta-Analysis.

Authors:  Lu Zhou; Wei-Ming Xiao; Cheng-Peng Li; Yi-Wen Gao; Wei-Juan Gong; Guo-Tao Lu
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

7.  ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1.

Authors:  Zhuo Shao; Chenggang Li; Qiao Wu; Xingmao Zhang; Yang Dai; Shenming Li; Xinyuan Liu; Xinying Zheng; Jiansheng Zhang; Hua Fan
Journal:  Oncogenesis       Date:  2022-08-04       Impact factor: 6.524

8.  PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic Cancer Patients Prior to Major Surgery.

Authors:  Veronica Marinelli; Olivia Purnima Danzi; Maria Angela Mazzi; Erica Secchettin; Massimiliano Tuveri; Deborah Bonamini; Michela Rimondini; Roberto Salvia; Claudio Bassi; Lidia Del Piccolo
Journal:  Front Psychol       Date:  2020-03-05

Review 9.  Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges.

Authors:  Sarah K Hakuno; Ellis Michiels; Eleonore B Kuhlemaijer; Ilse Rooman; Lukas J A C Hawinkels; Marije Slingerland
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.